Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor.
Anti-androgen drugs block androgen hormones, such as testosterone. People can use them for many purposes, like slowing prostate cancer and minimizing the masculinizing effects of certain hormones.
A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...
This medication is a beneficial addition to your prostate cancer treatment plan — but it doesn’t come without risks. Here’s how to stay ahead of potential side effects. If you’ve been diagnosed with ...
Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors We analyzed whole exomes of patient-matched pre- and ...
Intermittent androgen deprivation for prostate-specific antigen (PSA) elevation after radiotherapy may improve quality of life and delay hormone resistance. We assessed overall survival with ...
Hosted on MSN
Symptoms of androgen excess in women are too often being overlooked, or dismissed as 'just cosmetic'
Acne that won't go away. Hair thinning at the crown. Unwanted facial hair, unpredictable periods, mood swings and weight gain. For millions of women, these aren't just annoying symptoms—they're signs ...
Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. We investigated the effects of denosumab, a fully ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results